

NOW, THERE'S SUBSTANTIAL CLINICAL EVIDENCE: *MUSCULAR COUNTERPULSATION* CAN TREAT CHRONIC HEART FAILURE...

in a patient's home, with *m.pulse*®

Ronald C. Trahan

Conventional treatment of Chronic Heart Failure includes drugs, pacemakers, implanted circulatory support systems, and transplantation. All entail significant risks and side effects for the CHF patient. Now, clinical studies suggest there is a safe, effective and less costly alternative: *Muscular CounterPulsation* (MCP).



Journal of Cardiac Surgery
Vol. 24, No. 2, 2009
"Therapeutic value of muscular counterpulsation after coronary bypass grafting operation."



The International Journal of Artificial Organs
Vol. 31, No. 3, 2008
"ECG-triggered skeletal muscle stimulation improves hemodynamics and physical performance of heart failure patients."



The International Journal of Artificial Organs
Vol. 30, No. 5, 2007
"ECG-triggered muscular counterpulsation for treatment of low cardiac output."



European Journal of Cardio-Thoracic Surgery
Vol. 26, No. 4, 2004
"Muscular counterpulsation: preliminary results of a non-invasive alternative to intra-aortic balloon pump."



International Journal of Cardiology
Submitted
"Safety and efficacy of ECG-triggered muscular counterpulsation for hemodynamic improvement of cardiac function."

At present, conventional treatment for Chronic Heart Failure (CHF) include drugs and, in its advanced stages, surgical implants, and even heart transplantation. Not surprisingly, these treatment options are often associated with considerable side effects and great risks. Now, however, there is finally an alternative: the world's first and only noninvasive, effective and affordable treatment method that CHF patients can use in the comfort of their own home: *m.pulse*® with Muscular CounterPulsation (MCP). The novel device is being marketed in Europe to private practices as well as clinic- and hospital-associated cardiologists like Gunther Claus, MD, Chief of Internal Medicine and Cardiology at Asklepios Hospital outside Frankfurt, Germany. Dr. Claus's CHF patients rent the *m.pulse*® device from Cardiola, and he attends to any needed device adjustments and continually monitors its usage. "No doubt, many clinical studies have shown the safety and effectiveness of Muscular CounterPulsation in treating CHF," says Dr. Claus. "The device noninvasively reduces the heart's workload and increases blood flow to arteries that supply the heart muscle. In most cases, my patients use the device at home for 45 minutes a day, while they're sitting watching TV, for example." One of Dr. Claus' patients is a 66-year-old man who had numerous health issues. In addition to CHF, for example, he suffered from coronary artery disease, peripheral artery disease, edema, and diabetes. "He could barely walk 50 feet without having to stop and sit down because he'd be completely out of breath. He had large open wounds on both legs that hadn't healed in three years. And although he had participated in clinical drug trials before he came to me, nothing had helped him," said Dr. Claus. His patient's first *m.pulse*® treatment was conducted in Dr. Claus' office, with the patient sitting comfortably for 45 minutes. His *m.pulse*® treatment was repeated at home on a daily basis for the first month and has since been reduced to four treatments a week at home, with Dr. Claus closely monitoring his patient's progress with regular office visits. "His leg wounds are almost completely healed, and he can walk for about 1,000 feet before he needs to take a rest. It's incredible, actually," insists Dr. Claus. □



"Clinical trials have validated Muscular CounterPulsation as a safe and effective at-home treatment for Chronic Heart Failure,"

says Gunther Claus, MD, Chief of Internal Medicine and Cardiology at Asklepios Hospital, Melsungen (Frankfurt), Germany.

"Studies have shown that MCP may improve the physical performance of CHF patients up to 60%,"

says Otto M. Hess, MD, Professor of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland.